Zogenix grabs rare disease drug in $35M buyout; Angion withdraws IPO; Ultragenyx nabs orphan drug designation;

@FierceBiotech: Sarepta plunges as CEO moves goal line on Duchenne MD drug downfield. Report | Follow @FierceBiotech

@JohnCFierce: Les Echos and Bloomberg both say Viehbacher future in doubt at Sanofi ... among the chief irritants: Viehbacher's move to Boston. | Follow @JohnCFierce

@DamianFierce: Viehbacher's letter to the $SNY board is a wincing read. "Ask Len Schleifer about me!" | Follow @DamianFierce

@EmilyMFierce: Managers of discredited STAP stem cell study refund salary. More from Science | Follow @EmilyMFierce

> San Diego-based Zogenix has acquired the U.K.'s Brabant Pharma for $35 million in cash and stock. The buyout gives Zogenix the experimental drug Brabafen, which is designed to treat Dravet syndrome, a rare form of epilepsy. A small study involving 15 patients concluded that 93% of them were either seizure-free or demonstrated a much lower rate of seizures during treatment. Release

> Angion Biomedica became the latest biotech victim to cite unfavorable "market conditions" in withdrawing its attempt at an IPO. Story

> Rare disease specialist Ultragenyx Pharmaceutical reports that the FDA has granted its orphan drug designation for triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome. Release

Medical Device News

@FierceMedDev: ICYMI Friday: New microscope offers 3D cellular images that are fast, detailed and low toxicity. Article | Follow @FierceMedDev

@VarunSaxena2: Edwards profit up 23%, but increased TAVR competition looming. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

> St. Jude Medical snags FDA approval for next-generation ablation catheter. More

> Attorney: FDA final guidance on product recalls not helpful. Story

> Boston Children's Hospital debuts 'Baby MEG' brain imaging system. Article

Pharma News

@FiercePharma: EMA favors AstraZeneca's ovarian cancer drug Lynparza that FDA committee dissed. ICYMI Friday | Follow @FiercePharma

@EricPFierce: #Novorossiya gets subpoenaed for information about a manufacturing plant in #DenmarkHill. More | Follow @EricPFierce

@CarlyHFierce: Fed up with Allergan obstinance, Valeant CEO says he'd hike bid past $200 a share. News | Follow @CarlyHFierce

> Novartis unloads last piece of vaccines puzzle to CSL for $275M. Story

> Merck bogged down by slumping sales, but cuts deliver on profits. Article

> Is Viehbacher's job in danger? Some Sanofi directors are agitating for change, says Les Echos. Report

CRO News

> SRI's CRO cuts the ribbon on a new early-phase outpost. Item

> MPI buys out a CRO neighbor to bolster early-stage R&D. More

> CROs line up to advise Big Pharma's R&D think tank. Story

> WuXi teams up with Foundation Medicine to bring cancer profiling to China. Article

> Icon posts another revenue jump and dials up its expectations. Report

Biotech IT News

> Billionaire doc teams with Oxford Uni to build 'NASA of biomedicine.' More

> NIH-funded registry of patient-entered genetic data goes live. News

> 23andMe steps up R&D with new hire, poster push. Report

> Human Longevity backer creates $100M fund for 'crazy' ideas. Story

> Microsoft makes cloud-computing available to Ebola researchers. Article

Animal Health News

> USDA awards $4.5M to vets working in underserved areas. Article

> VCA beats Q3 estimates on same-store hospital sales growth. Report

> Are flea-fighting pills gaining ground on OTC topicals? Item

> K-State, Lawrence Livermore team on Dx tools to detect infectious diseases. Story

> Report: Pet owners jump on the probiotics bandwagon. More

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.